CCNB1 (cyclin B1)

2009-01-01   Carlos Perez-Stable 

Geriatric Research, Education,, Clinical Center, Research Service, Veterans Affairs Medical Center, Miami, FL, USA 33125





9 exons; 2,087 bp; 433 residues CCNB1 transcript 1.
8 exons; 1,833 bp; 397 residues CCNB1 transcript 2.


Two alternative transcripts resulting from distinct transcription initiation sites. One is constitutively expressed and the other is G2/M cell cycle-regulated.


No verified pseudogenes.



Cyclin B1 (48.337 kDa) is a member of the cyclin family of proteins whose levels vary during the cell cycle in order to activate specific cyclin-dependent kinases (CDKs) required for the proper progression through the cell cycle. Cyclin B1 protein begins to increase during G2, peaks in mitosis, and is rapidly degraded before the cell cycle is completed. Cyclin B1 interacts with CDK1 to form a complex known as the maturation-promoting factor (MPF), which is essential for cell cycle progression through mitosis. When chromosomes are properly aligned during anaphase, rapid degradation of cyclin B1 by anaphase-promoting complex/cyclosome (APC/C) is required for mitotic exit and completion of the cell cycle.


Cyclin B1 is overexpressed in a variety of cancers compared to normal cells and tissues. In normal tissues, low levels of cyclin B1 is detected in testis, thymus, bone marrow, and smooth muscle (CCNB1 expression). In most primary tumors, the expression of cyclin B1 is "unscheduled" (unrestricted to particular phases of the cycle), whereas in normal lymphocytes, the expression of cyclin B1 is restricted to very late S and G2 + M phases of the cell cycle (Gorczyca et al., 1997).


During interphase, cyclin B1 is concentrated in the cytoplasm but can shuttle to the nucleus (Pines and Hunter, 1991). At prophase, cyclin B1 accumulates in the nucleus and then to condensed chromatin, spindle microtubules, centrosomes, and chromatin during prometaphase (Bentley et al., 2007; Chen et al., 2008). This corresponds to localization of known CDK1 substrates, including nuclear lamins, microtubule and chromatin-associated proteins. Cyclin B1 is preferentially localized to unattached kinetochores and is involved in chromosome alignment in mitosis. In carcinomas, cytoplasmic expression of cyclin B1 is associated with a specific T-cell immune response (Egloff et al., 2006).
Atlas Image
Diagram of sequence domains for cyclin B1. The destruction box (DB) is required for degradation of cyclin B1 at the metaphase-to-anaphase transition. The cytoplasmic retention sequence (CRS) and the nuclear export signal (NES) are critical determinants of cyclin B1 localization during mitosis. The cyclin box is required for interaction with CDK1.


At entry into mitosis, cyclin B1-CDK1 promotes chromosome condensation, nuclear lamina resolution, and mitotic spindle assembly. Knockout mice without cyclin B1 or CDK1 are embryonic lethal, suggesting a requirement for cell proliferation (Brandeis et al., 1998). A long list of potential substrates for cyclin B1-CDK1 suggests other functions not yet known (CDK1 substrates).


Cyclin B1 is a member of the highly conserved cyclin family and cyclin AB subfamily. The cyclin box is a region of protein sequence homology that is common to all members of the cyclin family and is required for interaction with CDK partner. There are at least three G1 cyclins (cyclin C, cyclin D, cyclin E) and two G2/M cyclins (cyclin A, cyclin B). Cyclin B2 also interacts with CDK1 but is not required for cell proliferation (Brandeis et al., 1998). Cyclin B3 binds to CDK2 and appears to function in meiosis (Nguyen et al., 2002).



There are no known germinal or somatic mutations for cyclin B1 (CCNB1 COSMIC).

Implicated in

Entity name
Prostate Carcinoma
One study shows that the most powerful predictor of time to relapse of prostate cancer is a high ratio of cyclin A and B to the proliferation marker Ki67, i.e., the higher the ratio the longer time to relapse (Marshal et al., 1996). Another study, however, shows that high cyclin B1 expression in prostate cancer correlates with tumor grade and DNA ploidy but does not correlate with disease recurrence (Kallakury et al., 1999). Lower level of endogenous cyclin B1 increases the sensitivity of DNA mismatch repair-deficient prostate cancer cells to alkylating agents (Rasmussen et al., 2000). Overexpression of the oncogenic serine/threonine kinase PIM1 in prostate cancer cells increases cyclin B1 protein expression, which contributes to the development of polyploidy by delaying cytokinesis (Roh et al., 2005). The levels of cyclin B1 protein correlate with the ability of chemotherapy drugs to induce apoptosis of prostate cancer cells in vitro (Gomez et al., 2007).
Entity name
Breast Carcinoma
Treatment of MCF7 breast cancer cells with cyclin B1-specific antisense oligonucleotide blocks Taxol-induced apoptosis, suggesting that cyclin B1-associated CDK1 activity plays an important role in the induction of apoptosis by Taxol (Shen et al., 1998). Memory T cells specific for cyclin B1 peptides were isolated from patients with breast cancer (Kao et al., 2001). Nuclear cyclin B1-positive breast carcinoma is resistant to adjuvant therapy, and nuclear cyclin B1 immunoreactivity is a potent prognostic factor in breast carcinoma patients (Suzuki et al., 2007). However, another study did not find a correlation with cyclin B1 overexpression and a worse outcome in breast cancer patients (Peters et al., 2004). Downregulation of cyclin B1 inhibits proliferation of breast cancer cell lines and sensitizes to Taxol (Yuan et al., 2004; Androic et al., 2008).
Entity name
Non-Small Cell Lung Carcinoma (NSCLC)
Cyclin B1 is deregulated in NSCLC, particularly in the squamous cell carcinoma subtype (SCC), and a high level of cyclin B1 expression may be a prognostic marker for patients with early-stage SCC of the lung (Soria et al., 2000). Elevated levels of cyclin B1 expression may be an indicator of poor prognosis in NSCLC, particularly in non-SCC (Arinaga et al., 2003; Yoshida et al., 2004; Singhal et al., 2005). One study, however, did not find a prognostic relevance for cyclin B1 in NSCLC (Yoo et al., 2007).
Entity name
Small Cell Lung Carcinoma
Cyclin B1 expression closely correlates with the Ki-67 labeling index in small cell lung carcinomas, suggesting that cyclin B1 is one of the key factors regulating cell proliferation in pulmonary neuroendocrine tumors. However, cyclin B1 did not correlate with patient survival (Igarashi et al., 2004).
Entity name
Esophageal Squamous Cell Carcinoma (ESCC)
Cyclin B1 expression, especially nuclear, can be significant as a prognostic indicator in ESCC and may indicate a poor prognosis for patients (Murakami et al., 1999; Nozoe et al., 2002; Takeno et al., 2002). Isogenic ESCC cells overexpressing cyclin B1 reveal strong invasive growth and high potential of metastasis to lung in xenograft mice (Song et al., 2008).
Entity name
Head and Neck Squamous Carcinoma (HNSCC)
HNSCC overexpressing cyclin B1 may be resistant to radiation therapy and cyclin B1 may be an indicator of the risk of recurrence and metastasis in patients having HNSCC receiving radiation therapy (Hassan et al., 2002).
Entity name
Renal Cell Carcinoma (RCC)
Increased cyclin B1 in RCC and aberrant localization within the cytoplasm of tumor cells positively correlates with tumor progression, indicating the significant role of cyclin B1 in the development and pathogenesis of RCC. There may be prognostic value of cyclin B1 for RCC patients (Ikuerowo et al., 2006).
Entity name
Cervical Carcinoma
The relationship between human papillomavirus virus (HPV) typing and cyclin B1 expression was not significant in cervical intraepithelial neoplasia and invasive cancer (Hashiguchi et al., 2004). HPV-16 E1 E4 protein sequesters CDK1/cyclin B1 onto the cytokeratin network, prevents the accumulation of active CDK1/cyclin B1 complexes in the nucleus, and hence prevents mitosis. This may create an environment optimal for viral DNA replication (Davy et al., 2005). HPV-18 decreases the fidelity of mitotic checkpoints and increases CDK1-associated kinase activity relative to control populations. The G2 checkpoint is aberrant by virtue of the stabilization of cyclin B1 mRNA through the upregulation of HuR protein (Cho et al., 2006). Up-regulation of cyclin B1 expression occurs in cervical cancer and an aberrant expression of cyclin B1 might play an important role in cervical carcinogenesis (Zhao et al., 2006). Reduction of cyclin B1 in HeLa cervical carcinoma cell lines inhibits proliferation, induces apoptosis, and sensitizes to Taxol (Yuan et al., 2006).
Entity name
Ovarian Carcinoma
There is a significant correlation between percentages of polo-like kinase (PLK)-positive cells and histological grade of ovarian cancer. However, the expression of proliferating cell nuclear antigen, Ki-67, and cyclin B1 is independent of PLK expression (Takai et al., 2001).
Entity name
Pancreatic Cancer
Overexpression of CDK1, cyclin A, and cyclin B1 occurs in 54.8, 54.9 and 56.4%, respectively, of the pancreatic adenocarcinomas. The findings suggest that CDK1 and cyclin A play a role in the progression of pancreatic adenocarcinoma, while the clinical significance of cyclin B1 remains to be clarified because of its more random expression (Ito et al., 2002).
Entity name
Liver Cancer
Fifteen of 100 patients with hepatocellular carcinoma (HCC) have autoantibodies reactive with cyclin B1 (Covini et al., 1997). CDK1 overexpression is directly related to advanced stage, portal invasion, intrahepatic metastasis, poor differentiation, high alpha-fetoprotein level, large size, high Ki-67 labeling index, and poor prognosis. Cyclin A and B1 overexpression shows a similar tendency to that of CDK1, but they are not recognized as independent prognostic factors (Ito et al., 2000). Hepatitis C virus (HCV) proteins increase the activity of the cyclin B1-CDK1 complex via the p38 MAPK and JNK pathways and promotes nuclear import of cyclin B1 (Spaziani et al., 2006). TIS21 negatively regulates hepatocarcinogenesis in part by disruption of the FoxM1-cyclin B1 regulatory loop, thereby inhibiting proliferation of transformed cells developed in mouse and human livers (Park et al., 2008).
Entity name
Gastric Cancer
Cyclin B1 overexpression does not correlate with survival of patients with gastric cancer (Brien et al., 1998). Another study shows that cyclin B1 protein overexpression is closely associated with less aggressive gastric cancers (Yasuda et al., 2002). A third study shows that overexpression of cyclin B1 may play an important role in lymph node metastatic potential of gastric cancer (Kim, 2007).
Entity name
Colorectal Adenocarcinoma
The majority of colorectal cancers express high levels of cyclin B1, consistent with a high rate of cell proliferation (Wang et al., 1997). Cyclin B1 expression does not change in recurrent colorectal adenocarcinoma compared to primary tumors (Seong et al., 1999). A study suggests a close correlation between a lack of cyclin B1 immunostaining and a stronger metastatic behavior in colorectal cancer (Korenaga et al., 2002). Cyclin B1, but not cyclin G1, may promote colorectal carcinogenesis and later metastasis to lymph nodes (Li et al., 2003). High expression of cyclin B1 is a frequent and early event in colorectal carcinomas. However, cyclin B1 expression is neither a predictor of prognosis or survival in patients with colorectal cancer nor a suitable tool for identifying subgroups of patients at higher risk for disease recurrence (Grabsch et al., 2004; Bondi et al., 2005). Adenomatous polyposis coli (APC) is a substrate for recombinant human CDK1-cyclin B1, implicating phosphorylation as a mechanism for regulating APC function via a link to the cell cycle (Trzepacz et al., 1997).
Entity name
Thyroid Carcinoma
Cyclin B1 is overexpressed in four undifferentiated thyroid carcinomas (19.0%), but not in thyroid carcinomas of other types. CDK1 overexpression is also related to carcinoma differentiation (p < 0.0001), and is directly linked to cyclin A overexpression (p < 0.0001), but not to cyclin B1 overexpression (Ito et al., 2002). Cyclin B1 expression does not have any prognostic significance for poorly differentiated follicular thyroid carcinoma (Pulcrano et al., 2007).
Entity name
Tongue Carcinoma
Cyclin B1 is overexpressed in a subset of squamous cell carcinoma of the tongue and is associated with a more aggressive biological behavior of the disease (Hassan et al., 2001).
Entity name
Skin Melanoma
The expression of cyclin B1 (P < 0.0001) is significantly higher in melanomas in comparison with Spitz nevi (Stefanaki et al., 2007).
Entity name
Cyclin B1 is a gene identified to be increased in glioma cells invading brain slice cultures (Holtkamp et al., 2005). Human glioma tissue microarrays indicate a positive expression rate of CDK1/cyclin B1 with a positive correlation with pathologic grades (Chen et al., 2008).
Entity name
Nuclear and cytoplasmic cyclin B1 immunostaining correlates well with the tumor grade but shows poor correlation with Ki-67 in astrocytomas (Allan et al., 2000). There is a significant increase in cyclin B1 (P = 0.002) expression with increasing grade from diffuse astrocytoma through anaplastic astrocytoma to glioblastoma, suggesting a potential as a marker of tumor grade (Scott et al., 2005).
Entity name
Cyclin B1 expression shows no statistical significant effect on survival in medulloblastoma (Neben et al., 2004). Another study shows that the combined expression of MYC and the lactate dehydrogenase B (LDHB)/cyclin B1 gene signature is able to predict survival in medulloblastoma patients and are strong prognostic markers independent of the clinical parameters, metastasis, and residual disease (de Haas et al., 2008).
Entity name
E2F-1 overexpression in the U2OS osteosarcoma cell line increases cyclin B1, CDK1 activity, sensitivity to paclitaxel, and the cellular growth rate. Knockdown of cyclin B1 using an RNA interference decreases cellular growth rate and an increases resistance to paclitaxel (Russo et al., 2006).
Entity name
Leukemia and Lymphoma
Derangement of cyclin B1 and CDK1 kinetics and functions is more profound in Hodgkins disease than in anaplastic large cell lymphomas (Leoncini et al., 1998). Cyclin B1 and CDK1 appears to be involved in the genesis or progression of malignant lymphoma but only CDK1 is a useful marker for response to chemotherapy (Jin and Park, 2002). Overexpression of cyclin B1 in follicular lymphomas correlates with better response to chemotherapy (Bjorck et al., 2005). Nuclear and/or cytoplasmic staining in > or = 1% of diffuse large B-cell lymphoma cells is significantly associated with shorter overall survival (Obermann et al., 2005). Cyclin B1 protein accumulates in the nucleus of cells that are sensitive to gamma radiation-induced apoptosis (thymocytes, lymphoid cell lines), but remains cytoplasmic in apoptosis-resistant cells (primary and transformed fibroblasts) (Porter et al., 2003).
Entity name
Alzheimers Disease (AD)
Cyclin B1 and CDK1 are enriched in neurons with neurofibrillary tangles (NFT), characteristic of AD. This suggests that aberrantly reexpressed cyclin B1/CDK1 in NFT-bearing neurons in AD brain contributes to the generation of M-phase phospho-epitopes in NFT (Vincent et al., 1997). Cyclin B1 is not detected in control subjects but is expressed in subiculum, dentate gyrus, and CA1 region of patients with AD pathology (Nagy et al., 1997). Aberrant expression of cyclin B1 is identified in the hippocampus, subiculum, locus coeruleus, and dorsal raphe nuclei, but not inferotemporal cortex or cerebellum of AD cases. Control subjects show no significant expression of cyclin B1 in any of the six regions. Disregulation of various components of the cell cycle may be a significant contributor to regionally specific neuronal death in AD (Busser et al., 1998). Direct interactions between cyclin B1 and Abeta may provide potential mechanisms for the cytotoxicity of the Abeta peptide (Milton, 2002). CIP-1-associated regulator of cyclin B (CARB), a protein that associates with cyclin B1, increases in intraneuronal NFT neurofibrillary tangles in susceptible hippocampal and cortical neurons in AD. By marked contrast, CARB is found only at background levels in these neuronal populations in nondiseased age-matched controls (Zhu et al., 2004). Cdh1/Hct1, an activator of the E3-ubiquitin ligase anaphase-promoting complex (APC) that promotes the ubiquitylation and degradation of mitotic cyclins, is required to prevent the accumulation of cyclin B1 in terminally differentiated neurons. By keeping cyclin B1 low, Cdh1 prevents these neurons from entering an aberrant S phase that leads to apoptotic cell death. These results provide an explanation for the mechanism of cyclin B1 reactivation that occurs in the brain of patients suffering from AD (Almeida et al., 2005).
Entity name
Neurodegenerative Disease
Neurons containing characteristic neurodegenerative lesions in a subset of diseases including Down Syndrome, Frontotemporal Dementia linked to chromosome 17, Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinson-Amyotrophic Lateral Sclerosis of Guam, Niemann Pick disease type C, and Picks disease also display mitotic indices including cyclin B1 expression (Husseman et al., 2000).
Chromosome instability resulting from Tax-induced deficiency of cyclin B1 and securin may be the explanation for the highly aneuploid nature of adult T-cell leukemia cells (Liu et al., 2003).


Pubmed IDLast YearTitleAuthors
106567292000Overexpression of cyclin A and cyclin B1 proteins in astrocytomas.Allan K et al
161482192005Cdh1/Hct1-APC is essential for the survival of postmitotic neurons.Almeida A et al
191139922008Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.Androic I et al
128837112003Clinical implication of cyclin B1 in non-small cell lung cancer.Arinaga M et al
178817372007Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis.Bentley AM et al
155764762005High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma.Björck E et al
158581232005Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome.Bondi J et al
95397391998Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero.Brandeis M et al
97583671998Prognostic factors in gastric cancer.Brien TP et al
95259971998Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain.Busser J et al
182301522008Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo.Chen H et al
181957322008Cyclin B1 is localized to unattached kinetochores and contributes to efficient microtubule attachment and proper chromosome alignment during mitosis.Chen Q et al
164581132006Elevation of cyclin B1, active cdc2, and HuR in cervical neoplasia with human papillomavirus type 18 infection.Cho NH et al
89852681997Immune response to cyclin B1 in hepatocellular carcinoma.Covini G et al
157674022005Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes.Davy CE et al
163972062006Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.Egloff AM et al
175136022007Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.Gomez LA et al
91603101997Laser scanning cytometric analysis of cyclin B1 in primary human malignancies.Gorczyca W et al
154874472004Prognostic value of cyclin B1 protein expression in colorectal cancer.Grabsch H et al
152898422004Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia.Hashiguchi Y et al
124382262002Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma.Hassan KA et al
114898262001Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue.Hassan KA et al
161717882005Brain slice invasion model reveals genes differentially regulated in glioma invasion.Holtkamp N et al
111244252000Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases.Husseman JW et al
151540112004Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.Igarashi T et al
165575932006Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients.Ikuerowo SO et al
121230942002Expression of the G2-M modulators in pancreatic adenocarcinoma.Ito Y et al
121668962002Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation.Ito Y et al
120681342002Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications.Jin YH et al
101939481999The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.Kallakury BV et al
116965962001Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.Kao H et al
177222442007Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.Kim DH et al
118217972002The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer.Korenaga D et al
96636041998Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas: relation to the expression of p34cdc2 and cyclin B-1.Leoncini L et al
126846772003Cyclin B1, unlike cyclin G1, increases significantly during colorectal carcinogenesis and during later metastasis to lymph nodes.Li JQ et al
128610132003Human T-lymphotropic virus type 1 oncoprotein tax promotes unscheduled degradation of Pds1p/securin and Clb2p/cyclin B1 and causes chromosomal instability.Liu B et al
87975861996Expression of cell cycle-regulated proteins in prostate cancer.Mashal RD et al
119588602002The amyloid-beta peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity.Milton NG et al
100712501999Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma.Murakami H et al
92245241997Cell cycle markers in the hippocampus in Alzheimer's disease.Nagy Z et al
151263472004Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.Neben K et al
121850762002Characterization and expression of mammalian cyclin b3, a prepachytene meiotic cyclin.Nguyen TB et al
118959142002Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus.Nozoe T et al
162732392005Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.Obermann EC et al
183932922008TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop.Park TJ et al
154928072004Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.Peters MG et al
17174761991Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport.Pines J et al
124242022003Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis.Porter LA et al
176968342007Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification.Pulcrano M et al
108540602000The human cyclin B1 protein modulates sensitivity of DNA mismatch repair deficient prostate cancer cell lines to alkylating agents.Rasmussen LJ et al
162216672005Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1.Roh M et al
168495742006E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents.Russo AJ et al
177007002007Cdk1 is sufficient to drive the mammalian cell cycle.Santamaría D et al
161501172005Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology.Scott IS et al
106133091999Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas.Seong J et al
94383851998Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.Shen SC et al
159303322005Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.Singhal S et al
180483862008Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis.Song Y et al
109455972000Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.Soria JC et al
164463632006Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1.Spaziani A et al
174378892007Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.Stefanaki C et al
173592842007Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.Suzuki T et al
111669142001Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage.Takai N et al
121153752002Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma.Takeno S et al
92682941997Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34.Trzepacz C et al
91333821997Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain.Vincent I et al
90302521997Overexpression of cyclin B1 in human colorectal cancers.Wang A et al
122005972002Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study.Yasuda M et al
174499432007Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis.Yoo J et al
147601182004The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer.Yoshida T et al
162786752006Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.Yuan J et al
152086742004Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells.Yuan J et al
166147072006Expression profiling of cyclin B1 and D1 in cervical carcinoma.Zhao M et al
149918452004Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease.Zhu X et al
185939942008Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 Haas T et al

Other Information

Locus ID:

NCBI: 891
MIM: 123836
HGNC: 1579
Ensembl: ENSG00000134057


dbSNP: 891
ClinVar: 891
TCGA: ENSG00000134057


Gene IDTranscript IDUniprot

Expression (GTEx)



PathwaySourceExternal ID
Cell cycleKEGGko04110
p53 signaling pathwayKEGGko04115
Progesterone-mediated oocyte maturationKEGGko04914
Cell cycleKEGGhsa04110
p53 signaling pathwayKEGGhsa04115
Progesterone-mediated oocyte maturationKEGGhsa04914
Oocyte meiosisKEGGko04114
Oocyte meiosisKEGGhsa04114
FoxO signaling pathwayKEGGhsa04068
Cell cycle - G2/M transitionKEGGhsa_M00693
Cell cycle - G2/M transitionKEGGM00693
Gene ExpressionREACTOMER-HSA-74160
Generic Transcription PathwayREACTOMER-HSA-212436
Transcriptional Regulation by TP53REACTOMER-HSA-3700989
Cell CycleREACTOMER-HSA-1640170
Cell Cycle CheckpointsREACTOMER-HSA-69620
G2/M CheckpointsREACTOMER-HSA-69481
G2/M DNA damage checkpointREACTOMER-HSA-69473
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexREACTOMER-HSA-75035
G2/M DNA replication checkpointREACTOMER-HSA-69478
Cell Cycle, MitoticREACTOMER-HSA-69278
Mitotic G1-G1/S phasesREACTOMER-HSA-453279
G1/S TransitionREACTOMER-HSA-69206
E2F mediated regulation of DNA replicationREACTOMER-HSA-113510
E2F-enabled inhibition of pre-replication complex formationREACTOMER-HSA-113507
Mitotic G2-G2/M phasesREACTOMER-HSA-453274
G2/M TransitionREACTOMER-HSA-69275
Cyclin A/B1 associated events during G2/M transitionREACTOMER-HSA-69273
Regulation of PLK1 Activity at G2/M TransitionREACTOMER-HSA-2565942
Polo-like kinase mediated eventsREACTOMER-HSA-156711
Centrosome maturationREACTOMER-HSA-380287
Recruitment of mitotic centrosome proteins and complexesREACTOMER-HSA-380270
Recruitment of NuMA to mitotic centrosomesREACTOMER-HSA-380320
Mitotic ProphaseREACTOMER-HSA-68875
Golgi Cisternae Pericentriolar Stack ReorganizationREACTOMER-HSA-162658
Condensation of Prophase ChromosomesREACTOMER-HSA-2299718
MASTL Facilitates Mitotic ProgressionREACTOMER-HSA-2465910
Nuclear Envelope BreakdownREACTOMER-HSA-2980766
Activation of NIMA Kinases NEK9, NEK6, NEK7REACTOMER-HSA-2980767
Nuclear Pore Complex (NPC) DisassemblyREACTOMER-HSA-3301854
Depolymerisation of the Nuclear LaminaREACTOMER-HSA-4419969
Mitotic PrometaphaseREACTOMER-HSA-68877
Resolution of Sister Chromatid CohesionREACTOMER-HSA-2500257
Condensation of Prometaphase ChromosomesREACTOMER-HSA-2514853
Regulation of mitotic cell cycleREACTOMER-HSA-453276
APC/C-mediated degradation of cell cycle proteinsREACTOMER-HSA-174143
Regulation of APC/C activators between G1/S and early anaphaseREACTOMER-HSA-176408
Phosphorylation of Emi1REACTOMER-HSA-176417
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteinsREACTOMER-HSA-176814
Phosphorylation of the APC/CREACTOMER-HSA-176412
APC/C:Cdc20 mediated degradation of mitotic proteinsREACTOMER-HSA-176409
APC/C:Cdc20 mediated degradation of Cyclin BREACTOMER-HSA-174048
The role of GTSE1 in G2/M progression after G2 checkpointREACTOMER-HSA-8852276
TP53 Regulates Transcription of Cell Cycle GenesREACTOMER-HSA-6791312
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle ArrestREACTOMER-HSA-6804114

Protein levels (Protein atlas)

Not detected


Entity IDNameTypeEvidenceAssociationPKPDPMIDs


Pubmed IDYearTitleCitations
159313892005Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.297
204127692010Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis.272
205262822010Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest.143
173862612007Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.102
204041092010Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis.91
174666302007Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis.85
247466692014Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression.76
174724382007Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression.72
265064182016Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer.66
222861002012APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1.65


Carlos Perez-Stable

CCNB1 (cyclin B1)

Atlas Genet Cytogenet Oncol Haematol. 2009-01-01

Online version: